DOTATATE Acetate (CAS: 177943?89?4) – Purity 99.77% | GMP Factory

描述

DOTATATE acetate is a synthetic DOTA-conjugated octreotate peptide designed to target somatostatin receptor subtype 2 (SSTR2), which is highly expressed in neuroendocrine tumors (NETs). When labeled with radionuclides such as gallium-68 (^68Ga) or lutetium-177 (^177Lu), it becomes a powerful tool for PET imaging and peptide receptor radionuclide therapy (PRRT). This compound is essential in research for creating Radionuclide-Drug Conjugates (RDCs) and developing diagnostic or therapeutic radiopharmaceuticals.

Product Specifications

Mechanism of Action & Research Applications

DOTATATE acetate targets SSTR2-overexpressing cells, such as neuroendocrine tumors, through a high-affinity interaction. When radiolabeled, it facilitates PET imaging or PRRT by delivering diagnostic or therapeutic isotopes directly to tumor cells. This positioning makes it invaluable for:

• PET imaging development using ^68Ga-DOTATATE for high-resolution tumor localization

• PRRT research using ^177Lu-DOTATATE for targeted radionuclide therapy in laboratory models

• Designing next-generation radionuclide–drug conjugates (RDCs) for neuroendocrine tumor targeting

Side Effects (Research Reference Only)

In preclinical experiments, radiolabeled DOTATATE may cause:

• Cell damage through localized radiation (beta-particle mediated DNA breaks)

• Off-target radiation-induced effects in vitro
  These observations apply to model systems and do not reflect clinical safety.

Disclaimer

This product is strictly for laboratory research use. It is not approved for diagnostic, therapeutic, or human or veterinary use.